PBLS Stock: Price, Earnings History and SEC Filings
Parabilis Medicines, Inc. (PBLS) last traded at $28.32, down 1.32% on the latest session and down 12.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.13 against an analyst estimate of $-0.16, a miss of 1231.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PBLS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-2.13 | $-0.16 | -1231.25% |
PBLS beat the analyst EPS estimate in 0 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for PBLS
- 8-K · Sep 15, 2026Regulation FD disclosure
- 8-K · Sep 2, 2026Officer or director change
- 8-K · Aug 25, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 13, 2026
- 8-K · Aug 13, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 11, 2026Material agreement, Unregistered share sale, Bylaw change
- 424B4 · Jun 10, 2026
- S-1 · May 19, 2026
Insider filing activity
PBLS insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PBLS news
- Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology PotentialOct 27, 2026 · seekingalpha.com
- Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027Oct 24, 2026 · marketbeat.com
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorsOct 24, 2026 · finance.yahoo.com
- Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial UpdatesOct 20, 2026 · finance.yahoo.com
- Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial ExpandsOct 20, 2026 · finance.yahoo.com
- What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?Oct 20, 2026 · finance.yahoo.com
- Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For FreeOct 20, 2026 · seekingalpha.com
- Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor DrugOct 19, 2026 · tikr.com
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. (PBLS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.